Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1967 1
1968 1
1972 1
1975 1
1976 1
1977 4
1978 3
1979 2
1980 4
1981 3
1982 2
1983 3
1984 9
1985 11
1986 11
1987 10
1988 19
1989 17
1990 21
1991 20
1992 16
1993 23
1994 25
1995 25
1996 19
1997 31
1998 47
1999 43
2000 44
2001 69
2002 65
2003 55
2004 62
2005 85
2006 88
2007 84
2008 75
2009 67
2010 59
2011 65
2012 64
2013 66
2014 64
2015 68
2016 59
2017 57
2018 54
2019 52
2020 55
2021 62
2022 58
2023 61
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,763 results

Results by year

Filters applied: . Clear all
Page 1
Intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity: a systematic review and meta-analysis.
Shen SH, Jia X, Peng L, Zeng X, Shen H, Luo DY. Shen SH, et al. Int Urol Nephrol. 2022 Apr;54(4):737-747. doi: 10.1007/s11255-022-03129-0. Epub 2022 Feb 28. Int Urol Nephrol. 2022. PMID: 35226282 Review.
PURPOSE: To evaluate the effectiveness and safety of intravesical oxybutynin therapy for patients with neurogenic detrusor overactivity. ...Nineteen studies were included for analysis, of which 392 patients including both adults and children were treated with intravesical …
PURPOSE: To evaluate the effectiveness and safety of intravesical oxybutynin therapy for patients with neurogenic detrusor overactivi …
Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials.
El-Samahy M, Mouffokes A, Badawy MM, Amro S, Fayad T, Abdelwahab OA. El-Samahy M, et al. Arch Dermatol Res. 2023 Oct;315(8):2215-2226. doi: 10.1007/s00403-023-02587-5. Epub 2023 Mar 4. Arch Dermatol Res. 2023. PMID: 36869926 Free PMC article. Review.
RESULTS: Six studies were included in the meta-analysis, with a total of 293 patients. In all studies, patients were assigned to receive either Oxybutynin or Placebo. Oxybutynin represented an HDSS improvement (RR = 1.68 95% CI [1.21, 2.33], p = 0.002). ...CONCLUSIO …
RESULTS: Six studies were included in the meta-analysis, with a total of 293 patients. In all studies, patients were assigned to receive eit …
Transdermal oxybutynin.
Baldwin CM, Keating GM. Baldwin CM, et al. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. Drugs. 2009. PMID: 19275276 Review.
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ...*Transdermal oxybutynin is generally well tolerated in patients with overactive bladder. ...
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ... …
Oxybutynin topical and transdermal formulations: an update.
Staskin DR, Salvatore S. Staskin DR, et al. Drugs Today (Barc). 2010 Jun;46(6):417-25. doi: 10.1358/dot.2010.46.6.1487750. Drugs Today (Barc). 2010. PMID: 20571610 Review.
Oxybutynin, an antimuscarinic agent, is well established for the treatment of overactive bladder (OAB) and is the gold standard for the treatment of severe neurogenic bladder. ...Oxybutynin chloride topical gel (OTG) (Gelnique(R), Watson Pharmaceuticals, Corona, CA, …
Oxybutynin, an antimuscarinic agent, is well established for the treatment of overactive bladder (OAB) and is the gold standard for t …
[Oxybutynin-Kentera].
Duh D, Vandevijver A. Duh D, et al. J Pharm Belg. 2007;62(3):99-100. J Pharm Belg. 2007. PMID: 17955962 French. No abstract available.
Extended-release oxybutynin.
Comer AM, Goa KL. Comer AM, et al. Drugs Aging. 2000 Feb;16(2):149-55; discussion 156-7. doi: 10.2165/00002512-200016020-00008. Drugs Aging. 2000. PMID: 10755330 Review.
Extended-release oxybutynin (Ditropan XL) uses an osmotic system (OROS) to deliver a controlled amount of oxybutynin chloride into the gastrointestinal tract over a 24-hour period when taken once daily. ...Mean peak plasma concentrations are lower with extended-rele …
Extended-release oxybutynin (Ditropan XL) uses an osmotic system (OROS) to deliver a controlled amount of oxybutynin chloride …
Oxybutynin: past, present, and future.
Jirschele K, Sand PK. Jirschele K, et al. Int Urogynecol J. 2013 Apr;24(4):595-604. doi: 10.1007/s00192-012-1915-8. Epub 2012 Sep 14. Int Urogynecol J. 2013. PMID: 22976530 Review.
Oxybutynin chloride is primarily indicated for the treatment of overactive bladder syndrome (OAB). ...Currently, there are six different medications approved by the US Food and Drug Administration (FDA) for the treatment of OAB, with more than nine formulations including i …
Oxybutynin chloride is primarily indicated for the treatment of overactive bladder syndrome (OAB). ...Currently, there are six differ …
Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
Chancellor MB, Lucioni A, Staskin D. Chancellor MB, et al. Urology. 2024 Apr;186:123-129. doi: 10.1016/j.urology.2023.11.033. Epub 2024 Jan 29. Urology. 2024. PMID: 38296001 Free article. Review.
This review details the current literature regarding oxybutynin and cognition, including evidence from preclinical, clinical, and real-world studies that show that oxybutynin binds nonspecifically to muscarinic receptors in the brain and is associated with adverse c …
This review details the current literature regarding oxybutynin and cognition, including evidence from preclinical, clinical, and rea …
Oxybutynin chloride: alterations in drug delivery and improved therapeutic index.
Dmochowski R, Kell S, Staskin D. Dmochowski R, et al. Expert Opin Pharmacother. 2002 Apr;3(4):443-54. doi: 10.1517/14656566.3.4.443. Expert Opin Pharmacother. 2002. PMID: 11934349 Review.
Oxybutynin metabolism occurs primarily in the proximal gastrointestinal tract and the hepatic circulation and is mediated by the cytochrome P450 3A4 isozyme. ...Herein are reviewed the various pre- and post-approval trials which have documented the overall therapeutic inde …
Oxybutynin metabolism occurs primarily in the proximal gastrointestinal tract and the hepatic circulation and is mediated by the cyto …
1,763 results